Left Atrial Diameter and Atrial Ectopic Burden in Patients with Embolic Stroke of Undetermined Source: Risk Stratification of Atrial Fibrillation with Insertable Cardiac Monitor Analysis

Background and Purpose An insertable cardiac monitor (ICM) has been demonstrated to be a useful tool for detecting subclinical atrial fibrillation (AF) in patients with embolic stroke of undetermined source (ESUS). This study aimed to identify the clinical predictors of AF in ESUS patients with ICMs.

Methods We retrospectively selected consecutive patients with an ICM implanted for AF detection following ESUS. The primary endpoint was defined as any AF episode lasting for longer than 5 min. The atrial ectopic burden (AEB) was calculated as the percentage of the number of conducted QRS from atrial ectopy on Holter monitoring.

Results This study included 136 patients. AF lasting ≥ 5 min was detected in 20 patients (14.7%) during a median follow-up period of 6.6 months (interquartile range, 3.3–10.8 months). AF patients had a higher AEB (0.20% vs. 0.02%, p <0.001) and a larger left atrial diameter (LAD, 41.0 mm vs. 35.3 mm, p <0.001) than those without AF. The areas under the receiver operating characteristic curves were 0.795 and 0.816 for the LAD and log-transformed AEB, respectively, for the best cutoff values of 38.5 mm for LAD and 0.050% for AEB. AF lasting ≥ 5 min was detected in 34.6% (9/26) of patients with LAD ≥ 38.5 mm and AEB ≥ 0.050%, and in 0% (0/65) of those with LAD <38.5 mm and AEB <0.050%.

Conclusions AF was detected in a significant proportion of ESUS patients during a 6.6-month follow-up. The LAD and AEB are good predictors of AF and might be useful for AF risk stratification in ESUS patients.

Key Words stroke; atrial fibrillation; electrocardiography; monitoring, ambulatory.

INTRODUCTION

Despite ongoing technical advancements in imaging methods and improved pathophysiological understanding, the definitive cause of ischemic stroke remains inconclusive in 20–40% of cases.1,2 There is a large amount of evidence that thromboembolism accounts for most of these so-called cryptogenic strokes.2 This has led to the pragmatic clinical construct of embolic stroke of undetermined source (ESUS) being proposed, which is currently being used preferentially.2

Atrial fibrillation (AF) is the most common cause of cardioembolism and is therefore a potential cause of ESUS.2 Considering that oral anticoagulant (OAC) therapy substantially reduces the risk of recurrent stroke compared with aspirin and no treatment,4 identifying hidden AF is of paramount importance for the secondary prevention of stroke. However,
given that AF is often asymptomatic and occurs sporadically, it might not be identified in the prolonged electrocardiography (ECG) monitoring performed during hospitalization for acute stroke.

An insertable cardiac monitor (ICM) is a small device that is implanted in the subcutaneous layer of the anterior chest wall that allows continuous ambulatory ECG monitoring. An ICM has a sensitivity and negative predictive value of >95% in detecting AF, with AF episodes detected in approximately 20% of ESUS patients who were followed up for 2 years. Despite the good performance in detecting AF in patients with ESUS, the cost of ICM insertion remains high (approximately USD 10,000 in the USA). The cost-effectiveness of an ICM could be substantially improved if low-risk patients were excluded, because most of them do not benefit from the ICM. However, data regarding predictors of AF in this population are rare, and so the present study aimed to identify the predictors of AF in ESUS patients with an ICM.

**STUDY POPULATION AND DESIGN**

We retrospectively selected all consecutive ESUS patients who underwent ICM insertion for AF detection from March 1, 2016 to July 31, 2020 at our institution. The diagnosis of ESUS was established by neurologists when the patients satisfied the following criteria: nonlacunar brain infarction, open arteries (<50% stenosis) proximal to the infarct, and no major risk of cardioembolic source (AF or severe left ventricular dysfunction). The diagnostic assessment included brain computed tomography or magnetic resonance imaging showing a nonlacunar infarct, transthoracic echocardiography, 12-leads ECG and Holter monitoring for ≥24 h, and imaging of the extracranial and intracranial arteries supplying the area of the brain infarct. Demographic, clinical, laboratory, Holter, and echocardiographic data were obtained from a prospective stroke registry database or by reviewing electronic medical records. Patients who were lost to follow-up immediately after ICM implantation (e.g., due to transfer to another hospital) were excluded.

The primary endpoint was the detection of any AF episode lasting ≥5 min by ICM during follow-up. The period of 5 min is reportedly the shortest duration of AF that potentially increases the risk of stroke. The secondary endpoint was the longest duration of an AF episode per subject. The study patients were followed from the date of ICM implantation to the date of death or until July 31, 2020, whichever came first.

This study was approved by the Institutional Review Board (Approval number: B-2005/613-111) and conducted according to the principles of the Declaration of Helsinki. The need to obtain informed consent was waived due to the retrospective nature of the study and the minimal risk to the participants.

**METHODS**

**Calculation of CHA2DS2-VASc score**

The CHA2DS2-VASc score is one of several risk stratification systems for ischemia that can help determine the 1-year risk of a thromboembolic event in a nonanticoagulated patient with nonvalvular AF. The CHA2DS2-VASc score for stroke prediction was calculated as the summed score for the following medical conditions: 1 point each for congestive heart failure (“C”), hypertension (“H”), age (“A”) between 65 and 74 years, diabetes mellitus (“D”), female sex (“Sc”), and vascular disease (“V”); prior myocardial infarction or peripheral artery disease), and 2 points each for a history of stroke/transient ischemic attack/thromboembolism (“S”) or age ≥75 years (“A2”). Since the study participants had ESUS, all received a CHA2DS2-VASc score of at least 2 points.

**Calculation of the atrial ectopic burden**

The atrial ectopic burden (AEB) was calculated as follows based on the data from Holter monitoring (Pathfinder SL/Impresario Holter System, Spacelabs Healthcare, Snoqualmie, WA, USA) performed closest to the date of acute stroke (mostly during hospitalization):

\[
AEB(\%) = \frac{\text{Number of conducted QRS complexes from atrial ectopy}}{\text{Total number of QRS complexes}} \times 100.
\]
All arrhythmic episodes in Holter monitoring were reviewed independently by two electrophysiologists.

**Statistical analysis**

Categorical variables are presented as numbers and frequencies, while continuous variables are presented as mean±standard deviation values or median and interquartile range (IQR) values. Student’s t-test and the Kruskal-Wallis test were used to compare continuous variables according to whether or not they conformed to a normal distribution, while the chi-square test was used to compare categorical variables.

Kaplan-Meier curves were plotted to analyze the cumulative incidence of AF, and Cox proportional-hazards regression models were used to predict AF detection. Receiver operating characteristic (ROC) curve analysis was performed to assess the predictive accuracy of a variable in AF detection. If data did not conform to a normal distribution and were highly skewed (e.g., AEB), the values were log-transformed for Cox regression and ROC analysis. Statistical tests were performed using SPSS (version 22, IBM Corp., Armonk, NY, USA).

**RESULTS**

This study finally analyzed 136 patients after excluding 5 patients who were lost to follow-up or transferred to other hospitals. The median period between ESUS diagnosis and ICM implantation was 2.1 months (IQR, 0.3–8.9 months). During the median follow-up period of 6.6 months (IQR, 3.3–10.8 months) after ICM insertion, AF was detected in 25 patients (18.4%), among which 20 had an AF episode lasting ≥5 min (Fig. 1). The median period for detecting AF lasting ≥5 min was 15 days (IQR, 3–32 days). The Kaplan-Meier curve for the detection of AF lasting ≥5 min is shown in Fig. 2A. The median maximum duration of episodes lasting AF ≥5 min was 24.1 h (IQR, 15.4–33.8 h) (Fig. 2B). In contrast, the total duration of AF episodes in the five patients who had AF lasting <5 min was 2.5±1.0 min during the 10.4-month follow-up (data not shown).

Patients in whom AF lasted ≥5 min were older (70.4 years vs. 62.9 years, p=0.004) and had a higher AEB (0.20% vs. 0.02%, p<0.001), larger LAD (41.0 mm vs. 35.3 mm, p<0.001), and higher LAVI (46.5 mL/m² vs. 32.7 mL/m², p=0.004) than those without AF detection.

---

**Fig. 1.** Flow chart of AF detection after implanting an ICM. AF: atrial fibrillation, ESUS: embolic stroke of undetermined source, ICM: insertable cardiac monitor.

**Fig. 2.** Incidence and distribution of maximal duration of AF. Kaplan-Meier curve for AF detection in patients with embolic stroke of undetermined source (A) and maximum duration of AF episodes in individual patients (B). AF: atrial fibrillation.
without AF lasting ≥5 min (Table 1). The mean CHA2DS2-VASc score did not differ significantly between these two groups (4.5 vs. 4.0, p=0.101). OACs had been prescribed more frequently at discharge in patients who had AF lasting ≥5 min (10.0% vs. 1.7%, p=0.043). The detailed baseline characteristics are presented in Table 1.

### Atrial fibrillation prediction

In the univariable Cox proportion-hazards regression models, age [hazard ratio (HR), 1.043; 95% confidence interval (CI), 1.005–1.083], log-transformed AEB (HR, 2.724; 95% CI, 1.843–4.028), LAD (HR, 1.244; 95% CI, 1.137–1.362), and LAVI (HR, 1.040; 95% CI, 1.022–1.058) were significantly associated with AF lasting ≥5 min (Table 2). In the multivariable analysis, the log-transformed AEB (HR, 2.311; 95% CI, 1.463–3.649) and LAD (HR, 1.198; 95% CI, 1.085–1.323) were significantly associated with AF lasting ≥5 min.

The areas under the ROC curves for age, LAD, LAVI, and log-transformed AEB were 0.653, 0.795, 0.771, and 0.816, respectively (Fig. 3). The best cutoff values of LAD and AEB for detecting AF ≥5 min were 38.5 mm (sensitivity and specificity of 0.700 and 0.707, respectively) and 0.050% (0.725 and 0.691), respectively. When the AEB and LAD were plotted, no patient with LAD <38.5 mm and AEB <0.050% showed AF lasting ≥5 min during follow-up, whereas those with LAD ≥38.5 mm and AEB ≥0.050% showed an incidence of AF lasting ≥5 min of 34.6% (Fig. 4).

### DISCUSSION

This study assessed the incidence of AF in East Asian patients with ESUS, and tested the predictive accuracy of the AEB and LAD in detecting AF. The main findings can be summarized as follows: 1) during the median follow-up period of 6.6 months, significant AF (lasting ≥5 min) was detected in 14.7% of all ESUS patients with an ICM; 2) the AEB and LAD showed good predictive accuracy for AF; and 3) the AEB and LAD seem to improve the ability to determine the risk of hidden AF in ESUS.

The AF incidence in our study (14.7%) over a shorter follow-up is consistent with those found in previous studies (21.5–41% for 2–3 years of follow-up)\(^\text{3,6,11}\). Echocardiography and Holter

---

**Table 1.** Baseline characteristics of the study population

|                          | AF not detected (n=116) | AF detected (n=20) | p     |
|--------------------------|-------------------------|--------------------|-------|
| Age, years               | 62.9±14.0               | 70.4±9.3           | 0.004 |
| Female                   | 41 (35.3)               | 5 (25.0)           | 0.366 |
| Height, cm               | 164.0±9.5               | 163.2±9.6          | 0.711 |
| Weight, kg               | 66.7±11.0               | 65.1±11.8          | 0.751 |
| Body mass index, kg/m²   | 24.4±2.9                | 24.3±2.4           | 0.827 |
| Past history             |                         |                    |       |
| Hypertension             | 60 (51.7)               | 13 (65.0)          | 0.335 |
| Diabetes mellitus        | 31 (26.7)               | 7 (35.0)           | 0.446 |
| Myocardial infarction    | 0 (0.0)                 | 1 (5.0)            | 0.147 |
| Hypertrophic CMP         | 1 (0.9)                 | 0 (0.0)            | >0.999|
| CHA2DS2-VASc score       | 4.0±1.4                 | 4.5±1.5            | 0.101 |
| ECG PR interval, ms      | 177.1±27.3              | 186.3±49.5         | 0.230 |
| Holter monitoring        |                         |                    |       |
| Number of APCs           | 18 (6–67)               | 168 (37–1,326)     | <0.001|
| AEB, %                   | 0.021 (0.007–0.068)     | 0.199 (0.040–1.602)| <0.001|

**Echocardiography**

|                          |                          |                   |     |
|--------------------------|--------------------------|-------------------|-----|
| LVEF, %                  | 63.3±4.6                 | 62.7±5.8          | 0.608|
| LAD, mm                  | 35.3±5.2                 | 41.0±4.8          | <0.001|
| LAVI, mL/m²              | 32.7±8.5                 | 46.5±18.9         | 0.004|
| Patent foramen ovale     | 26 (22.4)                | 2 (10.0)          | 0.043|
| Discharge medication     |                          |                   |     |
| Aspirin                  | 94 (81.0)                | 15 (75.0)         | 0.532|
| Clopidogrel              | 59 (50.9)                | 7 (35.0)          | 0.190|
| OAC                      | 2 (1.7)                  | 2 (10.0)          | 0.043|
| Statin                   | 103 (88.8)               | 16 (80.0)         | 0.278|

Data are n (%), mean±standard-deviation, or median (interquartile range) values.

AEB: atrial ectopic burden, AF: atrial fibrillation, APCs: atrial premature complexes, CMP: cardiomyopathy, ECG: electrocardiography, LAD: left atrial diameter, LAVI: left atrium volume index, LVEF: left ventricular ejection fraction, OAC: oral anticoagulant.

**Table 2.** Cox proportional-hazards regression analysis of atrial fibrillation detection

|                          | **Univariable** | **Multivariable*** |
|--------------------------|-----------------|--------------------|
|                         | HR (95% CI)     | p                  | HR (95% CI)     | p                  |
| Age, years               | 1.043 (1.005–1.083) | 0.026              | 1.001 (0.959–1.044) | 0.977              |
| Log(AEB)                 | 2.724 (1.843–4.028) | <0.001             | 2.311 (1.463–3.649) | <0.001              |
| LAD, mm                  | 1.244 (1.137–1.362) | <0.001             | 1.198 (1.085–1.323) | <0.001              |
| LAVI, mL/m²              | 1.040 (1.022–1.058) | <0.001             |                   |                    |
| CHA2DS2-VASc score       | 1.261 (0.934–1.702) | 0.130              |                   |                    |

*Adjusted variables are age, log-transformed AEB, and LAD. LAVI exhibited collinearity with LAD. LAD was selected in the multivariable model due to its better prediction accuracy in the receiver operating characteristic analysis.

AEB: atrial ectopic burden, HR: hazard ratio, LAD: left atrial diameter, LAVI: left atrium volume index.
monitoring are essential screening examinations for assessing the cause of stroke, and the LAD and AEB can be easily obtained from these examinations. We consider our results to be valuable since they have yielded a novel risk prediction model that combines two variables known to be strongly associated with AF without requiring any additional costs or examinations.12-15

The cost-effectiveness of the ICM for the prevention of recurrent stroke in ESUS patients has been evaluated in several European countries and the USA,7,16 and is expected to vary with the socioeconomic status of different countries. In this study, the incidence of AF was 0% in patients with a LAD <38.5 mm and AEB <0.050%, who accounted for almost half (48%, 65/136) of the study participants. Theoretically, if these patients are excluded, the cost-effectiveness of an ICM would improve significantly. However, it is not possible to assess the AF risk precisely based on the present small-scale study, and so further large-scale studies are required to identify patients at a low risk of developing AF.

The prevalence of stroke increases with age, affecting 11.5% of males and 13.4% of females aged >80 years, and stroke mortality shows a similar trend with age.17 In addition, stroke sequelae significantly reduce the quality of life. No apparent cause was found in up to 40% of patients with ischemic stroke even after a proper workup.18 The rate of recurrent stroke was also high in this population, reaching 5.6% within 3 months19 and 14–20% within 2 years.20 Therefore, identifying AF is very important for the secondary prevention of stroke. A large randomized controlled trial including ESUS patients found that the AF detection rate was 12.4% in the ICM group and 2.0% in the control group.21 The current global guidelines include a Class IIa recommendation to use an ICM to document silent AF in patients with stroke, and state that OAC therapy should be implemented after AF is detected.4

**Fig. 3.** ROC curve analysis of age (A), LAD (B), LAVI (C), and log-transformed AEB (D) for atrial fibrillation detection. The LAD, LAVI, and log-transformed AEB showed a good predictive accuracy, with areas under the ROC curves of 0.795, 0.771, and 0.816, respectively. Log-transformed due to skewness of the data. AEB: atrial ectopic burden, LAD: left atrial diameter, LAVI: left atrium volume index, ROC: receiver operating characteristic.
There is no general agreement or established data on the causal relationship between AF duration and stroke. Short-lasting AF is unlikely to cause stroke. In a subgroup analysis of the Atrial Diagnostics Ancillary Study of the Mode Selection trial, patients with subclinical AF lasting ≥5 min had a 2.8-fold higher risk of the composite endpoint including stroke and death. In the Asymptomatic Atrial Fibrillation and Stroke Evaluation in Pacemaker Patients and the Atrial Fibrillation Reduction Atrial Pacing Trial, subclinical AF episodes lasting at least ≥24 h were associated with an increased risk of stroke. Another prospective observational study found that AF or an atrial tachycardia burden of ≥5.5 h/day (on any day) appeared to double the risk of thromboembolism. Based on these findings, current guidelines recommend initiating OAC therapy when subclinical AF lasts longer than 5 min after reviewing electrograms in patients with cardiac implantable electronic devices. However, previous studies involved patients with a pacemaker or implantable cardiac defibrillator, and so the obtained cutoff values for AF duration might not apply to ESUS patients. In the present study, among the 20 patients in whom AF was detected, 10 (50%) had AF episodes lasting ≥24 h and 17 (85%) had an AF episode lasting ≥5 h (data not shown). We speculate that these proportions would have increased if the patients had been followed up for longer.

This study had some limitations. First, it included a small population and was conducted at a single center. However, the median follow-up period of 6.6 months might have been sufficient to detect significant AF, because 18 of the 20 AF episodes were detected within 2 months. The optimal cutoff values of AEB and LAD for AF prediction may be different in studies with larger samples or longer follow-up durations. Second, a selection bias might have occurred because only those who agreed to undergo ICM insertion could be enrolled in the study. From January 1, 2019 to July 31, 2020, only 21.2% of patients with ESUS agreed to undergo ICM insertion in our institute, and those who refused may have had relatively unfavorable clinical characteristics such as older age and a higher comorbidity load. Third, the prediction model was based on data obtained from East Asians (e.g., LAD), and so it might not be applicable to other races with different anthropometric characteristics. Finally, the small number of events

---

**Fig. 4.** Scatter plot of the LAD and AEB according to AF detection. No AF was detected in patients with LAD <38.5 mm and AEB <0.050%. Patient with missing information on the AEB (n=1) was excluded. AEB: atrial ectopic burden, AF: atrial fibrillation, LAD: left atrial diameter.
In conclusion, this retrospective study detected AF in a significant proportion of ESUS patients with an ICM. The LAD and AEB had good predictive accuracy in detecting AF in ESUS patients. These parameters might be valuable for risk stratification prior to AF detection and for improving the cost-effectiveness of ICM utilization by excluding patients with a low probability of developing AF.

Author Contributions
Conceptualization: Ji Hyun Lee, In Tae Moon, Il-Young Oh. Data curation: Ji Hyun Lee, In Tae Moon. Formal analysis: Ji Hyun Lee, In Tae Moon. Investigation: Ji Hyun Lee, In Tae Moon. Methodology: Ji Hyun Lee, Youngjin Cho, Jun Yup Kim, Jihoon Kang, Beom Joon Kim. Project administration: Ji Hyun Lee, Il-Young Oh. Resources: Jun Yup Kim, Jihoon Kang, Beom Joon Kim, Moon-Ku Han, Hee-Joon Bae. Supervision: Ji Hyun Lee, Il-Young Oh, Hee-Joon Bae. Validation: Ji Hyun Lee, Il-Young Oh. Visualization: Ji Hyun Lee. Writing—original draft: In Tae Moon, Ji Hyun Lee. Writing—review & editing: Ji Hyun Lee, Il-Young Oh, Hee-Joon Bae.

ORCID iDs
Ji Hyun Lee https://orcid.org/0000-0002-7162-1248
In Tae Moon https://orcid.org/0000-0002-3847-0150
Youngjin Cho https://orcid.org/0000-0001-8106-3713
Jun Yup Kim https://orcid.org/0000-0003-4764-5714
Jihoon Kang https://orcid.org/0000-0001-5715-6610
Beom Joon Kim https://orcid.org/0000-0002-2719-3012
Moon-Ku Han https://orcid.org/0000-0003-0166-387X
Il-Young Oh https://orcid.org/0000-0002-5584-605X
Hee-Joon Bae https://orcid.org/0000-0003-0051-1997

Conflicts of Interest
The authors have no potential conflicts of interest to disclose.

Acknowledgements
We would like to thank Eun Jeong An and Yoon Joo Kim for their contribution in data collection and analysis.

REFERENCES
1. Finsterer J. Management of cryptogenic stroke. *Acta Neurol Belg* 2010; 110:135-147.
2. Hart RG, Diener HC, Coutts SB, Easton JD, Granger CB, O’Donnell MJ, et al. Embolic strokes of undetermined source: the case for a new clinical construct. *Lancet Neurol* 2014;13:429-438.
3. De Angelis MV, Di Stefano V, Franciotti R, Furia N, Di Girolamo E, Onofri M, et al. Cryptogenic stroke and atrial fibrillation in a real-world population: the role of insertable cardiac monitors. *Sci Rep* 2020; 10:3230.
4. Kirchhof P, Benussi S, Kotecha D, Ahlsson A, Atar D, Casadei B, et al. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. *Europace* 2016;18:1609-1678.
5. Giancaterino S, Lupercio F, Nishimura M, Hsu JC. Current and future use of insertable cardiac monitors. *JACC Clin Electrophysiol* 2018; 4:1383-1396.
6. Ziegler PD, Rogers JD, Ferreira SW, Nichols AJ, Richards M, Koehler JL, et al. Long-term detection of atrial fibrillation with insertable cardiac monitors in a real-world cryptogenic stroke population. *Int J Cardiol* 2017;244:173-179.
7. Maervoet J, Bossers N, Borge RP Jr, Hilpert ST, van Engen A, Smala A. Use of insertable cardiac monitors for the detection of atrial fibrillation in patients with cryptogenic stroke in the United States is cost-effective. *J Med Euron* 2019;22:1221-1234.
8. Kim BJ, Han MK, Park TH, Park SS, Lee KB, Lee BC, et al. Current status of acute stroke management in Korea: a report on a multicenter, comprehensive acute stroke registry. *Int J Stroke* 2014;9:514-518.
9. Glotzer TV, Hellkamp AS, Zimmerman J, Sweeney MO, Yee R, Marinchak R, et al. Atrial high rate episodes detected by pacemaker diagnostics predict death and stroke: report of the Atrial Diagnostics Ancillary Study of the MOde Selection Trial (MOST). *Circulation* 2003; 107:1614-1619.
10. Jiamsripong P, Honda T, Reuss CS, Hurst RT, Chalki HP, Grill DE, et al. Three methods for evaluation of left atrial volume. *Eur J Echocardiogr* 2008;9:351-355.
11. Brachmann J, Morillo CA, Sanna T, Di Lazzaro V, Diener HC, Bernstein RA, et al. Uncovering atrial fibrillation beyond short-term monitoring in cryptogenic stroke patients: three-year results from the cryptogenic stroke and underlying atrial fibrillation trial. *Circ Arrhythm Electrophysiol* 2016;9:e003333.
12. Soliman EZ, Howard G, Judd S, Bhave PD, Howard VJ, Herrington DM. Factors modifying the risk of atrial fibrillation associated with atrial premature complexes in patients with hypertension. *Am J Cardiol* 2020;125:1324-1331.
13. Gladstone DJ, Dorian P, Spring M, Panzov V, Mamdani M, Healey JS, et al. Atrial premature beats predict atrial fibrillation in cryptogenic stroke results: from the EMBRACE trial. *Stroke* 2015;46:936-941.
14. Thomas L, Abhayaratna WP. Left atrial reverse remodeling: mechanisms, evaluation, and clinical significance. *JACC Cardiovasc Imaging* 2017;10:65-77.
15. Vollmuth C, Stoeser S, Neugebauer H, Hansel A, Dreyhaupt J, Ludolph AC, et al. MR-imaging pattern is not a predictor of occult atrial fibrillation in patients with cryptogenic stroke. *J Neurol* 2019;266:3058-3064.
16. Diamantopoulos A, Sawyer LM, Lip GY, Witte KK, Fauchier L, et al. Cost-effectiveness of an insertable cardiac monitor to detect atrial fibrillation in patients with cryptogenic stroke. *Int J Stroke* 2016;11:302-312.
17. Benjamin EJ, Muntner P, Alonso A, Bittencourt MS, Callaway CW, Carson AP, et al. Heart disease and stroke statistics-2019 update: a report from the American Heart Association. *Circulation* 2019;139:e56-e528.
18. Yaghi S, Bernstein RA, Passman R, Okin PM, Furie KL. Cryptogenic stroke: research and practice. *Circ Res* 2017;120:527-540.
19. Lovett JK, Coulaj AJ, Rothwell PM. Early risk of recurrence by subtype of ischemic stroke in population-based incidence studies. *Neurology* 2004;62:569-573.
20. Kolominsky-Rabas PL, Weber M, Gefeller O, Neuendoerfer B, Heuschmann PU. Epidemiology of ischemic stroke subtypes according to TOAST criteria: incidence, recurrence, and long-term survival in ischemic stroke subtypes: a population-based study. *Stroke* 2001;32:2735-2740.
21. Sanna T, Diener HC, Passman RS, Di Lazzaro V, Bernstein RA, Morillo CA, et al. Cryptogenic stroke and underlying atrial fibrillation. *N Engl J Med* 2014;370:2478-2486.
22. Bridge F, Thijis V. How and when to screen for atrial fibrillation after stroke: insights from insertable cardiac monitoring devices. *J Stroke* 2016;18:121-128.
23. Van Gelder IC, Healey JS, Crijs HJGM, Wang J, Hohnloser SH, Gold MR, et al. Duration of device-detected subclinical atrial fibrillation and occurrence of stroke in ASSERT. *Eur Heart J* 2017;38:1339-1344.
24. Glotzer TV, Daoud EG, Wyse DG, Singer DE, Ezeckowitz MD, Hilker C, et al. The relationship between daily atrial tachyarrhythmia burden from implantable device diagnostics and stroke risk: the TRENDS study. *Circ Arrhythm Electrophysiol* 2009;2:474-480.